Guggenheim Issues Pessimistic Forecast for Immunome (NASDAQ:IMNM) Stock Price

Immunome (NASDAQ:IMNM) had its price target dropped by stock analysts at Guggenheim from $35.00 to $25.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 205.62% from the company’s current price.

Other equities research analysts have also issued reports about the company. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research report on Monday, March 10th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has a consensus rating of “Buy” and an average target price of $25.50.

Immunome Stock Down 5.5 %

Shares of IMNM opened at $8.18 on Thursday. Immunome has a 12-month low of $8.17 and a 12-month high of $26.70. The business’s fifty day moving average is $9.76 and its 200 day moving average is $11.57. The stock has a market cap of $652.58 million, a P/E ratio of -1.01 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last issued its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. On average, analysts expect that Immunome will post -2.21 EPS for the current year.

Insider Activity

In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several large investors have recently made changes to their positions in the business. FMR LLC increased its position in shares of Immunome by 0.3% during the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after purchasing an additional 13,757 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after purchasing an additional 324,614 shares during the last quarter. Enavate Sciences GP LLC purchased a new stake in shares of Immunome during the 4th quarter valued at $36,939,000. Price T Rowe Associates Inc. MD increased its position in shares of Immunome by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company’s stock valued at $24,243,000 after purchasing an additional 246,447 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Immunome by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company’s stock valued at $13,054,000 after purchasing an additional 21,396 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.